Ebronucimab vs Laroprovstat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ebronucimab
Marketed by Hubei Jumpcan Pharmaceutical and partners
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Reported efficacy
Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)
Result source: NCT05255094
Laroprovstat
Developed by AstraZeneca
NCT06173570 · Phase 2 · completed
The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).
Next expected readout: January 2027 · NCT07000136 (registry estimate)
Reported efficacy
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) (met)
Result source: NCT06173570
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ebronucimab | Laroprovstat |
|---|---|---|
| LDL-C, % change | —Not posted · NCT05260411 | -46.6% vs 4.1%−50.7 vs placeboNCT061735707 other results
|
| Non-HDL-C, % change | —Not posted · NCT05260411 | -41.6% vs 3.5%−45.2 vs placeboNCT061735707 other results
|
| ApoB, % change | —Not posted · NCT05260411 | -37.0% vs 2.9%−39.9 vs placeboNCT061735707 other results
|
| Lp(a), % change | —Not posted · NCT05260411 | -19.4% vs 0%−19.4 vs placeboNCT061735703 other results
|
| 3-point MACE (% with event) | —Not posted · NCT05260411 | —Trial running · NCT06834932 |
LDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- Laroprovstat
- -46.6% vs 4.1%−50.7 vs placeboNCT06173570
7 other results
- -41.1% vs 4.1% NCT06173570
- -33.8% vs 4.1% NCT06173570
- -31.2% vs 4.1% NCT06173570
- -46.4% vs 3.4% NCT06173570
- -40.5% vs 3.4% NCT06173570
- -33.4% vs 3.4% NCT06173570
- -30.5% vs 3.4% NCT06173570
Non-HDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- Laroprovstat
- -41.6% vs 3.5%−45.2 vs placeboNCT06173570
7 other results
- -41.4% vs 2.9% NCT06173570
- -35.1% vs 3.5% NCT06173570
- -34.8% vs 2.9% NCT06173570
- -29.9% vs 3.5% NCT06173570
- -29.4% vs 2.9% NCT06173570
- -26.9% vs 3.5% NCT06173570
- -26.1% vs 2.9% NCT06173570
ApoB, % change
- Ebronucimab
- —Not posted · NCT05260411
- Laroprovstat
- -37.0% vs 2.9%−39.9 vs placeboNCT06173570
7 other results
- -36.9% vs 2.4% NCT06173570
- -34.3% vs 2.9% NCT06173570
- -33.9% vs 2.4% NCT06173570
- -25.4% vs 2.9% NCT06173570
- -24.5% vs 2.4% NCT06173570
- -24.1% vs 2.9% NCT06173570
- -23.4% vs 2.4% NCT06173570
Lp(a), % change
- Ebronucimab
- —Not posted · NCT05260411
- Laroprovstat
- -19.4% vs 0%−19.4 vs placeboNCT06173570
3 other results
- -19.6% vs 0% NCT06173570
- -11.2% vs 0% NCT06173570
- -7.5% vs 0% NCT06173570
3-point MACE (% with event)
- Ebronucimab
- —Not posted · NCT05260411
- Laroprovstat
- —Trial running · NCT06834932
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ebronucimab: 0 of 4 rows · Laroprovstat: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ebronucimab | Laroprovstat |
|---|---|---|
| Dropout rate | — | 5.9%30 mga NCT06173570 · Phase 2 show 3 more results1.2%10 mg NCT06173570 · Phase 2 4.7%3 mg NCT06173570 · Phase 2 5.8%1 mg NCT06173570 · Phase 2 |
| Discontinued due to AEs | — | 2.4%30 mga NCT06173570 · Phase 2 show 3 more results0%10 mg NCT06173570 · Phase 2 0%3 mg NCT06173570 · Phase 2 1.2%1 mg NCT06173570 · Phase 2 |
| Serious AEs | — | 1.2%30 mga NCT06173570 · Phase 2 show 3 more results2.4%10 mg NCT06173570 · Phase 2 2.4%3 mg NCT06173570 · Phase 2 2.3%1 mg NCT06173570 · Phase 2 |
| Most frequent reported AEs | — | show 3 more results |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ebronucimab
show 1 more result
Laroprovstat
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Laroprovstat's landscape